Newsletter Signup


Email address
Secure and Spam free...
Mitigating Chemotherapy Resistance to Irinotecan, A Popular Topo I Inhibitor used in Treatment of Breast and Colon Cancer

Mitigating Chemotherapy Resistance to Irinotecan, A Popular Topo I Inhibitor used in Treatment of Breast and Colon Cancer

Researchers at the University of Sheffield have been investigating the causes for chemotherapy resistance in colon and breast cancer.  Their findings, recently published in Nucleic Acids Research, reveal that there is an epigenetically-driven process that speeds up the repair of DNA breakage caused during the course of chemotherapy, in this case with use of the Topo I inhibitor Irinotecan.  This process is referred to as “histone acetylation” and is treatable with clinically available therapeutics (HDAC Inhibitors).

Meisenberg, et al. (2016) Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.    Nucl. Acids Res. (2016) doi: 10.1093/nar/gkw1026 Published online October 26, 2016.

http://nar.oxfordjournals.org/content/early/2016/10/26/nar.gkw1026.full

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for The TopoGEN Newsletter


Email address
Secure and Spam free...